Piomic https://validator.w3.org/feed/docs/rss2.html Piomic receives the Seal of Excellence from the European Commission Home Global Page Piomic Medical AG has been awarded with the Innosuisse Label. 9th Balgrist Symposium on Diabetic Foot 20th SAfW Symposium – Advantages of COMS® technology Piomic signs Cooperation Agreement with the Geblog AG Rejelle Williams News Company COMS® Therapy Adrian Meier Sara Francisco Piomic selected as Ground-Breaking Swiss Startup Innovation Karina Candrian joins the Board of Directors Publication of COMS01 clinical trial results in the Journal of Wound Care Privacy Policy Mario Brückel Philipp Affeltranger Jari Kruth Bernard Laurel Martin Walti Christopher Hertz Our Product Home Bertrand Hughes Dr. Peter Hostettler Dominique Boulet Karina Candrian Dr. Jürg Fröhlich Order Bernard Laurel appointed as the President of Piomic Medical Inc. Pascale Stöcklin AMA granted unique U.S. CPT III reimbursement codes for concurrent optical and magnetic stimulation (COMS) Piomic receives Medicare Category B Designation for MAVERICKS clinical trial Piomic receives certification under MDR, the new European Medical Device Regulation FDA Breakthrough Device Designation for COMS® One Therapy System Piomic Medical closes oversubscribed financing round to bring COMS® therapy into US patients’ homes Bertrand Hughes appointed as the Chairman of the Board of Directors Piomic Medical receives unconditional FDA IDE approval for U.S. pivotal trial Piomic Medical Announces First Patients Enrolled in MAVERICKS Study Sites European KOLs Initiate NAZARÉ Post-Market Clinical Study Andy Weymann MAVERICKS IDE Trial Protocol Published in WOUNDS by Leading U.S. Experts New Study Reconfirms COMS® Effectiveness and Gives Insights to Potential New Applications for Wound Care Piomic Medical Secures Eurostars Financing for COMS® Blue Innosuisse State Secretariat for Education, Research and Innovation (SERI) Syntactx Piomic Medical Wins EPUAP 2024 Most Innovative Product Award